J&J partners with Pega to drive efficiencies in clinical research
Clinical trial growth has led to complexity managing multiple systems
Developed ClinApp to enable efficient planning and execution of trials
Currently in pilot phase with plans to scale in 2023
“Pega provides a unified user experience while being flexible enough to accommodate the study-specific details required to support pharmaceutical, medical technology, vision care, and surgical vision users across Johnson & Johnson.”
The Business Issue
Johnson & Johnson’s (J&J) Clinical Operations division collaborates with stakeholders across sectors to identify opportunities that improve efficiencies, broaden capabilities, and optimize the overall user experience in clinical research.
One area of focus has been the growth of clinical trials. The average number of clinical trial endpoints has been rising six percent annually since 2003, with the average protocol generating more than 20 unique endpoints. This may translate to millions of data points collected over the course of a study. In addition, the number of protocols, study sites, and patients have also increased significantly.
This growth has led to increased complexity due to multiple factors, including changing regulatory requirements, a high volume of operating procedures that vary by study type, and multiple systems used to manage clinical studies. This complexity creates challenges, including getting study information and updates when needed, delayed communication, and duplicative information across systems.
The company needed a more effective platform to manage clinical studies.
J&J partnered with Pega to develop ClinApp, a user-focused platform that provides an exceptional user experience through automation and integration of knowledge, processes, systems, and data. ClinApp reduces the complexity of work and enables the efficient planning and execution of clinical trials.
J&J chose the Pega Platform™ to deliver ClinApp because it enabled the team to overcome several technical challenges. Pega also provides a unified user experience while being flexible enough to accommodate the study-specific details required to support all clinical trial users across J&J.
Pega also enables users to manage business rules without requiring IT involvement for every change –integrating with a complex and evolving landscape of systems with a variety of technologies and capabilities.
ClinApp is still currently in its pilot phase, but J&J anticipates the following benefits of the new platform:
- Reduced time to complete tasks
- Less redundant work
- Improved compliance
- Exceptional user experience
Pega low-code app development.
See how the company transformed in 10 weeks.
Watch how the company digitized clinical trials with Pega.